ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2032

How Does Age At Onset Influence Autoimmune Rheumatic Diseases?

Jenny Amaya-Amaya1, Juan-Camilo Sarmiento-Monroy2, Nicolás Molano-González1, Mónica Rodríguez-Jiménez1, Rubén-Darío Mantilla2, Adriana Rojas-Villarraga1 and Juan-Manuel Anaya2, 1Center for Autoimmune Diseases Research (CREA), Universidad del Rosario., Bogota, Colombia, 2School of Medicine and Health Sciences, Universidad del Rosario. Center for Autoimmune Diseases Research (CREA), Bogotá, Colombia

Meeting: 2013 ACR/ARHP Annual Meeting

Keywords: rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE), Sjogren's syndrome

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Miscellaneous Rheumatic and Inflammatory Diseases II: Miscellaneous Rheumatic Diseases

Session Type: Abstract Submissions (ACR)

Background/Purpose: Age at onset of disease (AOD) refers to the time period at which a patient experiences the first sign (s) and symptom(s). AOD varies among autoimmune diseases (ADs) and has been related to prognosis in some of them. Genetic, epigenetic, and environmental factors may influence the AOD. The objective was to evaluate the influence of AOD on the clinical course and outcome in adult patients (> 17 years) with autoimmune rheumatic diseases, namely rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), and Sjögren’s syndrome (SS).

Methods: This was a cross sectional analytical study in which 1,082 consecutive adult patients fulfilling international criteria for RA (n=517), SLE (n=271), and SS (n=294) were included. Information on patients socio-demographic and cumulative clinical and laboratory data were obtained by interview, standardized report form, physical examination and chart review. Early AOD was categorized according to the lower quartileof AOD in every AD (i.e., 17-34 years in RA, 17-23 years in SLE, and 17-35 years in SS). Data were analysed by Fisher´s exact test, Chi square and Kruskal–Wallis test.

Results: There were significant differences between important demographic and clinical variables according to AOD (Table). Early AOD was associated with a more severe clinical course in RA and SLE. No relevant differences between early-SS and late-SS were observed. Late-AOD was associated with environmental exposure in RA and SLE. 

Conclusion: Our findings support the hypothesis of an influence of AOD on illness course in patients with ADs. Early-onset traits are more sensitive to genetic influence while late-onset to environmental variation. These results may serve to design better strategies aimed to discover the etiological factors of ADs.

Disease


Early-AOD 


Late-AOD 


RA           

Female

Higher educational level

Higher joint involvement

Extraarticular manifest

Environmental exposure

Cardiovascular disease

Higher body mass index

Higher waist to hip ratio

SLE

Cutaneous involvement

Antiphospholipid antibodies

Renal compromise 

Environmental exposure

SS Cutaneous vasculitis

Disclosure:

J. Amaya-Amaya,
None;

J. C. Sarmiento-Monroy,
None;

N. Molano-González,
None;

M. Rodríguez-Jiménez,
None;

R. D. Mantilla,
None;

A. Rojas-Villarraga,
None;

J. M. Anaya,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2013 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/how-does-age-at-onset-influence-autoimmune-rheumatic-diseases/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology